ESPR

2.57

0.00% 0.00

Handel nachbörslich: 2.57

Esperion Therapeutics Inc (ESPR)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt ESPR? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$2.57

Offen:

$2.52

24-Stunden-Volumen:

6.40M

Relative Volume:

1.70

Marktkapitalisierung:

$486.91M

Einnahmen:

$116.33M

Nettoeinkommen (Verlust:

$-209.25M

KGV:

-0.9113

EPS:

-2.82

Netto-Cashflow:

$-135.49M

1W Leistung:

+6.64%

1M Leistung:

+22.38%

6M Leistung:

+20.66%

1J Leistung:

+105.60%

1-Tages-Spanne:

$2.5106

$2.61

1-Wochen-Bereich:

$2.305

$2.615

52-Wochen-Spanne:

$1.1601

$3.40

Esperion Therapeutics Inc Stock (ESPR) Company Profile

Firmenname

Esperion Therapeutics Inc

Sektor

Healthcare (1182)

Branche

Drug Manufacturers - Specialty & Generic (86)

Telefon

734-887-3903

Adresse

3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR, MI

Mitarbeiter

240

Twitter

@esperioninc

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

ESPR's Discussions on Twitter

Vergleichen Sie ESPR mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ESPR Esperion Therapeutics Inc	2.57	486.91M	116.33M	-209.25M	-135.49M	-2.82
ZTS Zoetis Inc	175.70	79.27B	9.15B	2.43B	2.31B	4.92
HLN Haleon Plc Adr	9.59	43.23B	14.26B	1.55B	0	0.3327
TAK Takeda Pharmaceutical Co Adr	13.44	42.56B	30.27B	1.93B	3.45B	0.444
TEVA Teva Pharmaceutical Industries Ltd Adr	16.59	18.79B	16.77B	-959.00M	1.37B	-2.00
VTRS Viatris Inc	13.08	15.61B	15.05B	-883.30M	1.89B	1.53

Esperion Therapeutics Inc Stock (ESPR) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-06-20	Herabstufung	BofA Securities	Neutral → Underperform
2024-01-03	Herabstufung	BofA Securities	Buy → Neutral
2023-11-20	Fortgesetzt	JP Morgan	Neutral
2023-08-01	Hochstufung	Northland Capital	Under Perform → Market Perform
2023-06-15	Hochstufung	BofA Securities	Underperform → Buy
2023-03-16	Herabstufung	BofA Securities	Neutral → Underperform
2023-03-16	Herabstufung	Northland Capital	Market Perform → Under Perform
2023-03-07	Hochstufung	Credit Suisse	Underperform → Neutral
2023-02-27	Fortgesetzt	BofA Securities	Neutral
2023-02-24	Hochstufung	Jefferies	Hold → Buy
2023-02-03	Hochstufung	Morgan Stanley	Underweight → Equal-Weight
2022-08-03	Herabstufung	Credit Suisse	Neutral → Underperform
2022-05-05	Hochstufung	JP Morgan	Underweight → Neutral
2022-03-10	Eingeleitet	H.C. Wainwright	Buy
2021-10-19	Herabstufung	Credit Suisse	Outperform → Neutral
2021-10-14	Herabstufung	Morgan Stanley	Equal-Weight → Underweight
2021-05-05	Herabstufung	Stifel	Buy → Hold
2021-04-26	Fortgesetzt	Credit Suisse	Outperform
2021-03-11	Eingeleitet	Morgan Stanley	Equal-Weight
2021-02-12	Herabstufung	Jefferies	Buy → Hold
2021-02-09	Herabstufung	Goldman	Neutral → Sell
2021-01-15	Herabstufung	BofA Securities	Buy → Neutral
2020-11-10	Hochstufung	Credit Suisse	Neutral → Outperform
2020-09-29	Fortgesetzt	JP Morgan	Underweight
2020-08-11	Herabstufung	Credit Suisse	Outperform → Neutral
2020-04-01	Fortgesetzt	BofA/Merrill	Buy
2020-03-17	Hochstufung	Citigroup	Neutral → Buy
2020-02-24	Herabstufung	Northland Capital	Outperform → Market Perform
2020-02-14	Herabstufung	Citigroup	Buy → Neutral
2019-09-16	Hochstufung	Goldman	Sell → Neutral
2019-05-29	Herabstufung	Goldman	Neutral → Sell
2019-05-06	Hochstufung	BofA/Merrill	Underperform → Neutral
2019-04-26	Hochstufung	Goldman	Sell → Neutral
2019-03-13	Hochstufung	JP Morgan	Underweight → Neutral
2019-01-07	Bestätigt	Needham	Strong Buy
2018-12-13	Eingeleitet	Goldman	Sell
2018-10-29	Hochstufung	Northland Capital	Market Perform → Outperform
2018-10-16	Eingeleitet	BTIG Research	Buy
2018-08-17	Hochstufung	Citigroup	Neutral → Buy
2018-07-11	Herabstufung	Northland Capital	Outperform → Market Perform
2018-05-03	Herabstufung	JP Morgan	Neutral → Underweight
2018-05-02	Herabstufung	BofA/Merrill	Buy → Underperform

Alle ansehen

Esperion Therapeutics Inc Aktie (ESPR) Neueste Nachrichten

Nov 26, 2024

Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia - GlobeNewswire

Nov 26, 2024

Esperion's Cholesterol Drug Shows 25% LDL Reduction in Japan Trial, Advances to NDA | ESPR Stock News - StockTitan

Nov 26, 2024

Nov 21, 2024

Esperion to Participate in Upcoming Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire

Nov 21, 2024

Esperion to Present at Piper Sandler Healthcare Conference, Showcases Cardiovascular Pipeline | ESPR Stock News - StockTitan

Nov 21, 2024

Esperion's chief commercial officer sells shares worth $426 By Investing.com - Investing.com South Africa

Nov 21, 2024

Nov 20, 2024

Esperion's chief commercial officer sells shares worth $426 - Investing.com

Nov 20, 2024

Nov 19, 2024

Esperion Therapeutics (NASDAQ:ESPR) Earns Buy Rating from HC Wainwright - MarketBeat

Nov 19, 2024

Nov 18, 2024

Esperion Highlights New Exploratory Data from CLEAR Outcomes Trial Highlighting Value of NEXLETOL® (bempedoic acid) in Oral Featured Science Session and Multiple Poster Presentations at AHA Scientific Sessions 2024 - The Manila Times

Nov 18, 2024

Esperion Highlights New Exploratory Data from CLEAR - GlobeNewswire

Nov 18, 2024

Nov 15, 2024

Esperion Therapeutics (NASDAQ:ESPR) Rating Lowered to Hold at StockNews.com - MarketBeat

Nov 15, 2024

Nov 14, 2024

ESPR: 3 Growth Stocks Under $10 That Analysts Predict Will Skyrocket - StockNews.com

Nov 14, 2024

Two Seas Capital LP Acquires Significant Stake in Esperion Thera - GuruFocus.com

Nov 14, 2024

Nov 13, 2024

Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 09, 2024

Nov 08, 2024

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - StockTitan

Nov 08, 2024